Payment overview · 2025
General Payments
$327.03
17 reported records · 6 companies
Healthcare provider profile · identity verified
Troy David Brooks, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · STANTON, KY · NPI 1447364898
Verified facts
What the public records show
CMS Open Payments records show Troy David Brooks, P.A. received $327.03 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.57 | 44.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.08 | 30.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.48 | 9.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.85 | 5.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.06 | 5.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.99 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $327.03 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $146.57 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $65.47 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 80 |
| Lisinopril | Lisinopril | 260 | 70 |
| Losartan Potassium | Losartan Potassium | 231 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 198 | 58 |
| Montelukast Sodium | Montelukast Sodium | 193 | 56 |
| Omeprazole | Omeprazole | 189 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 55 |
| Gabapentin | Gabapentin | 172 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 48 |
| Ozempic | Semaglutide | 125 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 51 |
| Furosemide | Furosemide | 112 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 107 | 36 |
| Metformin Hcl Er | Metformin Hcl | 102 | 29 |
| Nifedipine Er | Nifedipine | 96 | 24 |
| Eliquis | Apixaban | 95 | 23 |
| Potassium Chloride | Potassium Chloride | 95 | 32 |
| Carvedilol | Carvedilol | 93 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 29 |
| Famotidine | Famotidine | 86 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 20 |
| Allopurinol | Allopurinol | 82 | 21 |
| Trazodone Hcl | Trazodone Hcl | 80 | 23 |
| Meloxicam | Meloxicam | 75 | 26 |
| Metformin Hcl | Metformin Hcl | 75 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 22 |
| Sertraline Hcl | Sertraline Hcl | 68 | 19 |
| Atenolol | Atenolol | 67 | 18 |
| Glimepiride | Glimepiride | 66 | 18 |
| Ezetimibe | Ezetimibe | 65 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 20 |
| Tramadol Hcl | Tramadol Hcl | 63 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 18 |
| Pregabalin | Pregabalin | 60 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 17 |
| Januvia | Sitagliptin Phosphate | 58 | 16 |
| Clonazepam | Clonazepam | 56 | 11 |
| Chlorthalidone | Chlorthalidone | 55 | 18 |
| Mirtazapine | Mirtazapine | 54 | 21 |
| Jardiance | Empagliflozin | 52 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 13 |
| Finasteride | Finasteride | 50 | 18 |
| Simvastatin | Simvastatin | 50 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 11 |
| Prednisone | Prednisone | 43 | 19 |
| Alprazolam | Alprazolam | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 14 |
| Donepezil Hcl | Donepezil Hcl | 39 | 13 |
| Meclizine Hcl | Meclizine Hcl | 38 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 17 |
| Bumetanide | Bumetanide | 36 | 16 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 11 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Spironolactone | Spironolactone | 34 | 14 |
| Cefdinir | Cefdinir | 33 | 29 |
| Bupropion Xl | Bupropion Hcl | 30 | 13 |
| Linzess | Linaclotide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Nystatin | Nystatin | 21 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 18 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Mupirocin | Mupirocin | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $327.03 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error